{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-081592","form_type":"8-K","ticker":"CUE","cik":"0001645460","company_name":"Cue Biopharma, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.179650+00:00","generated_at":"2026-05-23T14:42:14.699562+00:00","sec_items":["1.01","2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cue Biopharma prices $20M public offering; $13.1M cash; runway into Q2 2026","bullets":["Pricing of 13.53M common shares + warrants at $0.79/unit; $20M gross proceeds.","Net proceeds estimated at $18M; closing expected April 16, 2025.","Preliminary cash and cash equivalents of $13.1M as of March 31, 2025 (unaudited).","Including $12M upfront from Boehringer Ingelheim deal, cash runway extended into Q2 2026.","Offering includes pre-funded warrants for 11.47M shares at $0.001 exercise price."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-081592","json":"https://secwatch.observer/filing/0001193125-25-081592.json","markdown":"https://secwatch.observer/filing/0001193125-25-081592.md","text":"https://secwatch.observer/filing/0001193125-25-081592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/0001193125-25-081592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645460/000119312525081592/d923668d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:42:14.699562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}